drugset

drugset / Trial / NCT00498914

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914 ↗

Phase 2 Terminated 41 enrolled Astellas Pharma Inc

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Timeline

Start: 2007-06
Primary completion: 2009-04
Completion: 2009-04

Outcome

Outcome not reported

Stopped: “Futility boundary at interim analysis not met”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SEPANTRONIUM	Small molecule	—	Intravenous

Indications